Drugs / Recombinant Streptokinase
Recombinant Streptokinase
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT00968929 | Jun 2006 → May 2009 | pulmonary embolism | Beijing Chao Yang Hospital | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Streptokinase | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00968929 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant streptokinase (r-SK) is an effective thrombolytic agent developed with gene engineering.” NCT00968929 ↗ |
| Route | Intravenous | “continuously intravenous infusion” NCT00968929 ↗ |